485.36 USD
+6.43 (+1.34%)
At close: Feb 6, 2026
485.36 USD
0 (0%)
After Hours: 2/6/2026, 8:10:05 PM
UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR has a decent growth rate and is not valued too expensively. This makes UTHR very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- UTHR had positive earnings in the past year.
- In the past year UTHR had a positive cash flow from operations.
- Each year in the past 5 years UTHR has been profitable.
- UTHR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of UTHR (17.30%) is better than 95.99% of its industry peers.
- UTHR's Return On Equity of 19.30% is amongst the best of the industry. UTHR outperforms 95.61% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 17.33%, UTHR belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for UTHR is below the industry average of 18.12%.
- The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
- UTHR has a better Profit Margin (40.65%) than 97.14% of its industry peers.
- In the last couple of years the Profit Margin of UTHR has grown nicely.
- UTHR has a Operating Margin of 48.65%. This is amongst the best in the industry. UTHR outperforms 99.62% of its industry peers.
- UTHR's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 88.59%, UTHR belongs to the best of the industry, outperforming 90.65% of the companies in the same industry.
- In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- UTHR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
- UTHR has more shares outstanding than it did 5 years ago.
- UTHR has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 19.41 indicates that UTHR is not in any danger for bankruptcy at the moment.
- UTHR has a better Altman-Z score (19.41) than 89.69% of its industry peers.
- UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.41 |
ROIC/WACC1.97
WACC8.79%
2.3 Liquidity
- A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 6.40, UTHR is in the better half of the industry, outperforming 65.27% of the companies in the same industry.
- UTHR has a Quick Ratio of 6.07. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
- UTHR has a Quick ratio of 6.07. This is in the better half of the industry: UTHR outperforms 64.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
- UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.90%, which is quite good.
- UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.88% yearly.
- Looking at the last year, UTHR shows a quite strong growth in Revenue. The Revenue has grown by 13.50% in the last year.
- UTHR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.71% yearly.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
- UTHR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.57% yearly.
- UTHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y12.48%
EPS Next 2Y9.45%
EPS Next 3Y8.97%
EPS Next 5Y11.57%
Revenue Next Year11.46%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.21%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 18.39, UTHR is valued on the expensive side.
- 95.04% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
- UTHR is valuated rather cheaply when we compare the Price/Earnings ratio to 27.92, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 16.47, the valuation of UTHR can be described as correct.
- Based on the Price/Forward Earnings ratio, UTHR is valued cheaply inside the industry as 95.61% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (27.78), we can say UTHR is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.39 | ||
| Fwd PE | 16.47 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaply inside the industry as 96.95% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, UTHR is valued cheaper than 95.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.72 | ||
| EV/EBITDA | 10.24 |
4.3 Compensation for Growth
- UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.47
PEG (5Y)1.09
EPS Next 2Y9.45%
EPS Next 3Y8.97%
5. Dividend
5.1 Amount
- UTHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
485.36
+6.43 (+1.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners98.84%
Inst Owner Change-1.34%
Ins Owners1.84%
Ins Owner Change-2.85%
Market Cap20.90B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target539.75 (11.21%)
Short Float %4.23%
Short Ratio4.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)3.77%
PT rev (3m)8.04%
EPS NQ rev (1m)-0.85%
EPS NQ rev (3m)1.47%
EPS NY rev (1m)0.23%
EPS NY rev (3m)-1.48%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)1.2%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.39 | ||
| Fwd PE | 16.47 | ||
| P/S | 6.68 | ||
| P/FCF | 18.72 | ||
| P/OCF | 13.43 | ||
| P/B | 3.17 | ||
| P/tB | 3.23 | ||
| EV/EBITDA | 10.24 |
EPS(TTM)26.39
EY5.44%
EPS(NY)29.47
Fwd EY6.07%
FCF(TTM)25.93
FCFY5.34%
OCF(TTM)36.14
OCFY7.45%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.47
PEG (5Y)1.09
Graham Number301.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 19.41 |
F-Score8
WACC8.79%
ROIC/WACC1.97
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.48%
EPS Next 2Y9.45%
EPS Next 3Y8.97%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.46%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.45%
EBIT Next 3Y8.03%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?
ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.
Can you provide the profitability details for UNITED THERAPEUTICS CORP?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
What are the PE and PB ratios of UNITED THERAPEUTICS CORP (UTHR) stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 18.39 and the Price/Book (PB) ratio is 3.17.
What is the expected EPS growth for UNITED THERAPEUTICS CORP (UTHR) stock?
The Earnings per Share (EPS) of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 12.48% in the next year.